Agenus Inc. announced that Jean-Marie Cuillerot, M.D. was appointed Chief Medical Officer. Dr. Cuillerot initially joined Agenus in 2016 as the Vice President and Global Head of Clinical Development. As CMO Dr. Cuillerot will be responsible for shaping the company's clinical development strategy to ensure alignment with corporate objectives. He will oversee a number of clinical-stage programs including those involving CTLA-4 antagonist (AGEN1884) as well as programs that are rapidly approaching the clinic such as the PD-1 antagonist antibody (AGEN2034), the AutoSynVax vaccine candidate and a series of novel checkpoint antibody molecules.